Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is Bristol-Myers Squibb's Dividend Unbeatable?

There's a lot that goes into a great dividend stock, but it all starts out with a great dividend yield that you can trust to be there for the long term. Big pharma's an industry with a number of top dividend stocks, with cash flow aplenty and a history of dividend raises among some of the biggest names -- but with sales under pressure because of the patent cliff, this sector's fallen under scrutiny among long-term income investors. Bristol-Myers Squibb (NYSE: BMY  ) is one stock with a great dividend that's withstood the blow of patent expirations, but can this dividend make you rich in the long run?

The loss of former top-selling drug Plavix's patent protection has slammed Bristol's performance, but the company's looking to brighter days in the future. Bristol's gearing up its pipeline with new candidates to deliver strong sales for the long run, and no drug under this company's development looks stronger right now than potential cancer-fighting therapy nivolumab. Analysts have pegged nivolumab's peak sales at up to $4 billion or more, and despite shifting moods around Wall Street over this drug lately, it's still among Bristol's best shot at sustaining and growing its dividend for years to come.

Yet does Bristol have more than just nivolumab to keep dividend investors happy? Take a look at what's making Bristol's dividend go, and what can keep it rising far into the future, in the following video, as Motley Fool contributor Dan Carroll takes you through the ins and outs of this big pharma stock with plenty of appeal to income investors.

Don't miss these top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2965785, ~/Articles/ArticleHandler.aspx, 9/3/2015 9:11:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Carroll

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,351.38 293.03 0.00%
S&P 500 1,948.86 35.01 0.00%
NASD 4,749.98 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 4:02 PM
BMY $59.61 Down +0.00 +0.00%
Bristol-Myers Squi… CAPS Rating: ****
AZN $31.68 Down +0.00 +0.00%
AstraZeneca plc (A… CAPS Rating: ****